- Cancer Types
Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Cancer A to Z - Cancer Treatment
Cancer Treatment
Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
- Risk and Prevention
- Cancer Drugs
- Support
Support
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
- Healthcare Professionals
- Clinical Trials
My Patient Treatment Binder
OncoLink Blogs
What's My Cancer Risk?
OncoPilot: Navigating Your Cancer Journey
Community Events Calendar
OncoLink eNews
Abramson Cancer Center
NCI CANCERLIT® Search: Plasma Cell Neoplasm - August 2002
National Cancer Institute®
Last Modified: August 1, 2002
- Clinical images: osteosclerotic myeloma associated with the POEMS syndrome.
- Myeloma and monoclonal gammopathy of uncertain significance associated with acquired von Willebrand's syndrome. Seven new cases with a
- Thalidomide in the treatment of multiple myeloma.
- AEterna reports on its phase II trial of neovastat.
- Nonsecretory multiple myeloma.
- Leptomeningeal relapse of multiple myeloma following allogeneic stem cell transplantation.
- Angiogenesis in multiple myeloma.
- Cytokines modulate telomerase activity in a human multiple myeloma cell line.
- Administration of a modified chemotherapeutic regimen containing vincristine, liposomal doxorubicin and dexamethasone to multiple myeloma
- Tamoxifen-based treatment induces clinically meaningful responses in multiple myeloma patients with relapsing disease after
- The presence of circulating clonal CD19+ cells in multiple myeloma.
- [Diagnostic image (86). A man with thirst and diplopia]
- Plasma cell dyscrasias and the head and neck.
- Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma.
- Radiologic findings of multiple myeloma with gastric involvement: a case report.
- Immunohistochemical localization of phosphorylated AKT in multiple myeloma.
- [Plasma cell infiltration of the liver in multiple myeloma]
- Human Genome Sciences announces clearance of IND application for LymphoRad.
- Fine needle aspiration cytology of extramedullary plasmacytoma.
- Multiple myeloma and mycosis fungoides in the same patient: clinical, immunologic, and molecular studies.
- [An association of multiple myeloma and megaloblastic anemia]
- [A new case of association of multiple myeloma and megaloblastic anemia]
- Acquired cutis laxa associated with multiple myeloma.
- Ifosfamide encephalopathy presenting with asterixis.
- [Tumor producing amylase]
- Transverse syndrome as the dominant feature of solitary cervical plasmocytoma with dissemination.
- Incidental finding of myeloproliferative disorders during sternotomy.
- Pseudohyperphosphataemia in multiple myeloma.
- Pseudohyperphosphataemia in multiple myeloma.
- Pseudohyperphosphataemia in multiple myeloma.
- Marked and sustained improvement of systemic sclerosis following polychemotherapy for coexistent multiple myeloma.
- The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of
- Proliferation, apoptosis, and intratumoral vascularity in multiple myeloma: correlation with the clinical stage and cytological grade.
- beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells.
- Current therapy for multiple myeloma.
- Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with multiple myeloma. A phase II International Oncology Study Group study.
- Absence of biologically important Kaposi sarcoma-associated herpesvirus gene products and virus-specific cellular immune responses in multiple
- [A case of multiple myeloma with infiltration into skeletal muscle after injections of a granulocyte-colony stimulating-factor]
Table of Contents
1
UI - 12124883
AU - Chung JB; Albert DA
TI -
Clinical images: osteosclerotic myeloma associated with the POEMS
syndrome.
SO - Arthritis Rheum 2002 Jul;46(7):1968
AD - University of Pennsylvania, Philadelphia, PA, USA.
2
UI - 11858359
AU - Lamboley V; Zabraniecki L; Sie P; Pourrat J; Fournie B
TI -
Myeloma and monoclonal gammopathy of uncertain significance associated
with acquired von Willebrand's syndrome. Seven new cases with a
literature review.
SO - Joint Bone Spine 2002 Jan;69(1):62-7
AD - Department of rheumatology, CHU Purpan, Toulouse, France.
OBJECTIVES: Acquired von Willebrand's syndrome (AvWS) is an uncommon
complication of monoclonal gammopathy of uncertain significance (MGUS)
or myeloma. We investigated clinical and laboratory test abnormalities,
pathophysiological hypotheses, and treatment options in this poorly
known condition. PATIENTS: Five patients with MGUS and two with myeloma
who met classic criteria for acquired von Willebrand's syndrome were
included in this retrospective study. RESULTS: Acquired von Willebrand's
syndrome was diagnosed before the gammopathy in five of the seven
patients. The severity of the bleeding events was chiefly dependent on
the degree of von Willebrand's factor deficiency and on the presence or
absence of gastrointestinal tract angiodysplasia. Bleeding event
severity was similar in patients with nonmalignant and malignant
disease. An antibody that inhibited von Willebrand's factor was detected
in all seven patients. Clotting returned to normal after treatment of
the malignancy in one of the two patients with myeloma. In patients with
MGUS, treatment is warranted only when bleeding occurs or before
surgery. Von Willebrand's factor concentrates were of limited efficacy
because of their short half-life. Intravenous immunoglobulins had a
longer-lasting effect (about 3 weeks); this treatment was used on a
regular basis in two patients with recurrent bleeding. CONCLUSIONS: A
diagnosis of von Willebrand's syndrome in adulthood should prompt a
search for a monoclonal gammopathy. In patients with gammopathies,
simple clotting tests ensure the diagnosis of acquired von Willebrand's
syndrome.
3
UI - 12113124
AU - Rajkumar SV
TI -
Thalidomide in the treatment of multiple myeloma.
SO - Expert Rev Anticancer Ther 2001 Jun;1(1):20-8
AD - Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN
55905, USA. rajks@mayo.edu
Thalidomide--banned from clinical use in the 1960s because of severe
teratogenicity--is now back in clinical practice as an effective agent
in the treatment of relapsed and refractory multiple myeloma. Several
clinical trials have determined that thalidomide is active in 25-35% of
patients with relapsed myeloma. The role of thalidomide in early-stage
myeloma is being actively investigated. Thalidomide has antiangiogenic
and immunomodulatory properties and is an effective inhibitor of
TNF-alpha. However, the mechanism of its action in myeloma remains
unclear. Major toxicities of thalidomide include constipation, sedation,
skin rash, fatigue and peripheral neuropathy. This paper summarizes the
current status of thalidomide in multiple myeloma.
4
UI - 12113128
AU - Anonymous
TI -
AEterna reports on its phase II trial of neovastat.
SO - Expert Rev Anticancer Ther 2001 Jun;1(1):3-4
5
UI - 12144086
AU - Abdalla IA; Tabbara IA
TI -
Nonsecretory multiple myeloma.
SO - South Med J 2002 Jul;95(7):761-4
AD - Bone Marrow Transplant Program, George Washington University Medical
Center, Washington, DC 20037, USA.
Nonsecretory multiple myeloma (NSMM) is a rare variant of the classic
form of multiple myeloma (MM) and accounts for 1% to 5% of all cases of
MM. The clinical presentation and radiographic findings of NSMM and MM
are the same. The diagnosis of MM requires the detection of a monoclonal
gammopathy in the serum or urine. In NSMM, however, no such gammopathy
can be demonstrated, making the diagnosis more difficult. We describe a
43-year-old African American woman who initially had back pain and
pathologic vertebral compression fractures that were thought to be due
to osteoporosis. Five months later, hypercalcemia developed and NSMM was
diagnosed. No monoclonal gammopathy was found in the serum or urine, but
skeletal survey showed diffuse osteolytic lesions, and bone marrow
biopsy revealed marked plasmacytosis. The immunohistochemical techniques
and chromosomal analysis methods that are currently available are
discussed.
6
UI - 12008088
AU - Savage DG; Mears JG; Balmaceda C; Rescigno J; Shendrik I; Mansukhani M;
TI -
Orazi A
Leptomeningeal relapse of multiple myeloma following allogeneic stem
cell transplantation.
SO - Leuk Res 2002 Jul;26(7):689-92
AD - Hematology/Oncology Division, Columbia University College of Physicians
and Surgeons, 177 Fort Washington Avenue, New York City, NY 10032, USA.
savege@cancercenter.columbia.edu
Progressive multiple myeloma may manifest features of
'de-differentiation', including a plasmablastic appearance, failure to
secrete paraprotein, extramedullary involvement, and resistance to
treatment. A 44-year-old woman with kappa-light chain myeloma underwent
allogeneic stem cell transplantation (SCT). Twenty months later she
developed paraspinal plasmablastic myeloma in the absence of paraprotein
in urine or myeloma in the marrow. The paraspinal masses responded to
chemotherapy. At 30 months she developed myelomatous meningitis, which
proved resistant to intrathecal chemotherapy, irradiation, and donor
lymphocyte infusion (DLI). The leptomeningeal disease led to death at 38
months. This is the first report of leptomeningeal relapse of myeloma
after allografting.
7
UI - 12008091
AU - Sezer O; Niemoller K; Jakob C; Heider U
TI -
Angiogenesis in multiple myeloma.
SO - Leuk Res 2002 Jul;26(7):701-2
8
UI - 12097303
AU - Akiyama M; Hideshima T; Hayashi T; Tai YT; Mitsiades CS; Mitsiades N;
TI -
Chauhan D; Richardson P; Munshi NC; Anderson KC
Cytokines modulate telomerase activity in a human multiple myeloma cell
line.
SO - Cancer Res 2002 Jul 1;62(13):3876-82
AD - Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology,
Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
Telomerase is a ribonucleoprotein DNA polymerase that elongates the
telomeres of chromosomes to compensate for losses that occur with each
round of DNA replication and maintain chromosomal stability. Interleukin
6 (IL-6) and insulin-like growth factor 1 (IGF-1) are proliferative and
survival factors for human multiple myeloma (MM) cells. To date,
however, the effects of IGF-1 and IL-6 on telomerase activity and
associated sequelae in MM cells have not been characterized. In this
study, we evaluated the effects of IGF-1 and IL-6 on telomerase activity
in MM cell lines (MM.1S, U266, and RPMI 8226), as well as patient MM
cells. We show that these cytokines up-regulate telomerase activity
without alteration of human telomerase reverse transcriptase (hTERT)
protein expression. We also demonstrate that increased telomerase
activity triggered by these cytokines is mediated by
phosphatidylinositol 3'-kinase (PI3k)/Akt/nuclear factor kappaB
(NFkappaB) signaling. We confirm involvement of PI3k/Akt/NFkappaB
signaling because the PI3k inhibitors wortmannin and LY294002 or the
inhibitor of NFkappaB (IkappaB) kinase inhibitor PS-1145 block
constitutive and cytokine-induced up-regulation of telomerase activity.
Furthermore, we show that dexamethasone (Dex) reduces telomerase
activity through the inhibition of hTERT expression before the induction
of apoptosis. Importantly, IGF-1 and IL-6 abrogate Dex-induced
down-regulation of telomerase activity and apoptosis. The protective
effect of those cytokines against Dex-induced down-regulation of
telomerase activity is blocked by both wortmannin and PS-1145, whereas
the protection against Dex-induced apoptosis is blocked by wortmannin
but not PS-1145. Therefore, our results demonstrate that telomerase
activity is related not only to transcriptional regulation of hTERT by
NFkappaB but also to posttranscriptional regulation because of
phosphorylation of hTERT by Akt kinase. These studies therefore
demonstrate that telomerase activity is associated with cell growth,
survival, and drug resistance in MM cells.
9
UI - 10966172
AU - Tsiara SN; Kapsali E; Christou L; Panteli A; Pritsivelis N; Bourantas KL
TI -
Administration of a modified chemotherapeutic regimen containing
vincristine, liposomal doxorubicin and dexamethasone to multiple myeloma
patients: preliminary data.
SO - Eur J Haematol 2000 Aug;65(2):118-22
AD - Haematology Unit, University of Ioannina, Greece. stsiara@cc.uoi.gr
For elderly patients with multiple myeloma (MM), conventional melphalan
and prednisone (MP) therapy has been the treatment of choice; the
vincristine, doxorubicin and dexamethasone (VAD) regimen is preferred
for younger patients who also receive high-dose melphalan in combination
with autologous or allogeneic bone marrow transplantation (BMT).
Although survival time is similar in both the MP and VAD regimens, the
continuous infusion of doxorubicin which the latter treatment entails
constitutes a disadvantage along with the 4-day hospitalization
required. Doxorubicin also induces cardiotoxicity, particularly in the
elderly. A modified form of VAD therapy includes liposomal doxorubicin
(Caelyx) (40 mg/m2 for 1 d) [corrected], oncovin (2 mg for 1 d) and
dexamethasone 40 mg for 4 d per os. Doxorubicin encapsulated with
liposomes has less cardiotoxicity, is more efficient and has fewer side
effects than conventional doxorubicin, and it can be administered on an
outpatient basis: dexamethasone can be given orally and vincristine in
bolus infusion. In order to estimate its efficacy and tolerability, we
administered this regimen to 12 patients (first-line treatment in 6
patients, salvage therapy in 6 patients). All patients exhibited good
tolerance to liposomal doxorubicin with no severe side effects. Eight
patients achieved complete hematological remission and three partial
response. One patient died before completing the treatment. In
conclusion, compared to other therapies, this modified VAD regimen
containing liposomal doxorubicin can be more easily administered to MM
patients, without severe side effects and with increased full remission
rates, almost similar to those with the conventional VAD treatment.
10
UI - 11911415
AU - Fassas AB; Rapoport AP; Bolanos-Meade J; Shanholtz C; Cottler-Fox M;
TI -
Tricot G
Tamoxifen-based treatment induces clinically meaningful responses in
multiple myeloma patients with relapsing disease after
autotransplantation.
SO - Leuk Lymphoma 2001 Nov-Dec;42(6):1323-8
AD - Department of Internal Medicine, Greenebaum Cancer Center, University of
Maryland, Baltimore, USA. fassasathanasios@uams.edu
Tamoxifen has been shown to induce apoptosis in multiple myeloma cell
lines and primary myeloma cells. Daily tamoxifen was given to 12
consecutive multiple myeloma patients who either relapsed following
autologous stem cell transplantation (11) or had progressive disease on
conventional chemotherapy (1). Methotrexate was also given biweekly to
enhance the antiangiogenetic effect. Two patients achieved complete
remission lasting 8 and 18 months. Two additional patients had stable
disease (SD) for 7 and 11 months. All responders were men and the
earliest signs of response were seen after approximately 6-8 weeks of
treatment. The regimen was very well tolerated. Speculations about a
possible mechanism of action of tamoxifen in multiple myeloma are
discussed.
11
UI - 11911420
AU - Rasmussen T
TI -
The presence of circulating clonal CD19+ cells in multiple myeloma.
SO - Leuk Lymphoma 2001 Nov-Dec;42(6):1359-66
AD - Department of Hematology L, Herlev Hospital, University of Copenhagen,
Herlev, Denmark. thra@herlevhosp.kbhamt.dk
Multiple myeloma (MM) is a B-cell malignancy characterized by the
expansion of mature plasma cells (PC) localized in the bone marrow (BM).
Several studies have identified circulating clonotypic CD19+ cells at a
differentiation stage preceding the PC. The level of circulating
clonotypic CD19+ cells is highly variable but generally low. Circulating
clonotypic cells respond well to induction therapy, although a small
subset within the CD19 compartment is resistant even to high-dose
chemotherapy. The clonal CD19+ cells represent an ongoing
differentiating population ranging from memory B-cells to plasmablasts.
However, a clonal relationship gives no proof of malignant potential,
and whether or not clonotypic precursor cells are involved in the
disease process is a subject of intense debate. Translocations involving
the immunoglobulin locus (14q32) are an early non-transforming event
common to both monoclonal gammopathy of undetermined significance (MGUS)
and MM introduced at the memory B-cell level. At the plasmablast stage,
a phenotypic transformation occurs with downregulation of CD19 and
upregulation of myeloma specific markers such as CD56, CD117 and CD28.
Translocations involving the isotype-switch machinery and the
introduction of tumor-specific markers at the plasmablast stage suggest
that the clonal CD19+ memory B-cells and CD19+ plasmablasts are
non-malignant, but immortalized relatives that gave rise to myeloma. A
final proof of the malignant potential of CD19+ clonotypic cells might
await the identification of the molecular events causing the
transformation in myeloma.
12
UI - 12014238
AU - van Soest EJ; de Klerk G
TI -
[Diagnostic image (86). A man with thirst and diplopia]
SO - Ned Tijdschr Geneeskd 2002 Apr 27;146(17):803
A 71-year-old man was thirsty, had bone pains and a double vision.
Multiple myeloma with hypercalcemia was diagnosed. One tumour in the
clivus turned out to be compressing the left N. abducens.
13
UI - 12004363
AU - Batsakis JG; Medeiros JL; Luna MA; El-Naggar AK
TI -
Plasma cell dyscrasias and the head and neck.
SO - Ann Diagn Pathol 2002 Apr;6(2):129-40
AD - Department of Pathology, University of Texas M. D. Anderson Cancer
Center, Houston 77004, USA.
Structures in the head and neck (bones, soft tissues, lymph nodes,
mucosa) are variably affected by plasma cell dyscrasias. Involvement can
be manifested by localized lesions (extramedullary plasmacytoma or
solitary plasmacytoma of bone) or by more diffuse disease (multiple
myeloma). We present a contemporary review of these disorders with
emphasis on patient outcomes. Copyright 2002, Elsevier Science (USA).
All rights reserved.
14
UI - 12037117
AU - Curley MJ; Hussein SA; Hassoun PM
TI -
Disseminated herpes simplex virus and varicella zoster virus coinfection
in a patient taking thalidomide for relapsed multiple myeloma.
SO - J Clin Microbiol 2002 Jun;40(6):2302-4
AD - Pulmonary and Critical Care Division, New England Medical Center,
Boston, Massachusetts 02111, USA.
Disseminated herpes simplex virus (HSV) and varicella zoster virus (VZV)
have been reported individually in immunosuppressed adults. We present a
case of coinfection with disseminated HSV and VZV infection in a patient
taking thalidomide for relapsed multiple myeloma. This is the first
report of opportunistic infection associated with thalidomide.
15
UI - 12087204
AU - Kwak HS; Jin GY; Lee JM
TI -
Radiologic findings of multiple myeloma with gastric involvement: a case
report.
SO - Korean J Radiol 2002 Apr-Jun;3(2):133-5
AD - Department of Diagnostic Radiology, Chonbuk National University
Hospital, Korea.
We report a case of multiple myeloma with gastric involvement occurring
in a patient who underwent an upper gastrointestinal series (UGIS), CT
and MRI. UGIS depicted a luminal protruding mass, while
contrast-enhanced CT demonstrated marked thickening of the gastric wall,
with subtle contrast enhancement. At T1- and T2-weighted MR imaging, the
mass showed iso- and intermediate signal intensity, respectively. After
the administration of contrast material, subtle homogeneous enhancement
was apparent.
16
UI - 11902142
AU - Alkan S; Izban KF
TI -
Immunohistochemical localization of phosphorylated AKT in multiple
myeloma.
SO - Blood 2002 Mar 15;99(6):2278-9
17
UI - 12098098
AU - Sucker C; Dolken G; Preuss J; Schwesinger G; Stockschlader M
TI -
[Plasma cell infiltration of the liver in multiple myeloma]
SO - Dtsch Med Wochenschr 2002 Jul 5;127(27):1469-72
AD - Klinik und Poliklinik fur Innere Medizin C, Germany.
sucker@uni-greifswald.de
18
UI - 12113047
AU - Anonymous
TI -
Human Genome Sciences announces clearance of IND application for
LymphoRad.
SO - Expert Rev Anticancer Ther 2002 Jun;2(3):246-7
19
UI - 12146056
AU - Rege JD; Aditya GS; Shet TM
TI -
Fine needle aspiration cytology of extramedullary plasmacytoma.
SO - Acta Cytol 2002 Jul-Aug;46(4):789-90
20
UI - 12107563
AU - Gernone A; Frassanito MA; Pellegrino A; Vacca A; Dammacco F
TI -
Multiple myeloma and mycosis fungoides in the same patient: clinical,
immunologic, and molecular studies.
SO - Ann Hematol 2002 Jun;81(6):326-31
AD - Department of Biomedical Sciences and Human Oncology, University of Bari
Medical School, Section of Internal Medicine and Clinical Oncology,
Piazza G. Cesare, 11, 70124 Bari, Italy.
The coexistence of multiple myeloma (MM) and mycosis fungoides (MF), and
hence of both B- and T-cell neoplastic clones, is a rare event. We
describe a case of plaque-stage MF associated with IgG lambda MM. The
clinical onset of MF preceded that of MM, supporting the hypothesis that
MF predisposed to the development of the B-cell proliferative disorder.
The skin tumor cells were found to originate from CD4(+) T-lymphocytes,
characterized by a V beta 8 receptor and no proviral human
T-lymphotropic virus (HTLV)-I monoclonal integration. They also
displayed a polarized Th1-type cytokine profile containing mRNAs for
interleukin (IL)-2, interferon (IFN)-gamma, and tumor necrosis factor
(TNF)-beta, but not for IL-4, IL-5, or IL-10. The CD8(+)/CD57(+)
suppressor-cytotoxic subpopulation was significantly increased in the
peripheral blood and was associated with MM progression. Expression of
p16INK4A, a gene from the INK family that inhibits cyclin-dependent
kinases and regulates the cell cycle, was lacking in MF cells and bone
marrow (BM) plasma cells. The p16INK4A gene was silenced by
hypermethylation, suggesting that it plays a role in the early phase of
the pathogenesis of both diseases. Thus, a lymphoid precursor cell
presumably contains aberrations that induce the development of both
clonal diseases in a multistep process.
21
UI - 10089658
AU - Marcos Sanchez F; Solano Ramos F; Juarez Ucelay F; Arranz Nieto MJ;
TI -
Duran Perez-Navarro A
[An association of multiple myeloma and megaloblastic anemia]
SO - An Med Interna 1999 Jan;16(1):51-2
22
UI - 10686722
AU - Miramon Lopez J; Ruiz Cantero A; Morales Jimenez J; Lara Fernandez A;
TI -
Hita Perez J
[A new case of association of multiple myeloma and megaloblastic anemia]
SO - An Med Interna 1999 Dec;16(12):654-5; discussion 656
23
UI - 11868975
AU - Gupta A; Helm TN
TI -
Acquired cutis laxa associated with multiple myeloma.
SO - Cutis 2002 Feb;69(2):114-8
AD - State University of New York at Buffalo School of Medicine, USA.
Cutis laxa is an uncommon condition characterized by loose and redundant
skin. Biopsy results are positive for a reduction in or an absence of
elastic fibers in the dermis. Cutis laxa is acquired or congenital. The
acquired form is either a generalized insidious form (type I) or a form
associated with prior inflammation (type II). Cardiovascular, pulmonary,
gastrointestinal, and urologic complications may occur. In the past,
cutis laxa was associated with plasma cell dyscrasia. We report on a
characteristic cause of cutis laxa to alert clinicians to this uncommon
manifestation of multiple myeloma.
24
UI - 12084448
AU - Meyer T; Ludolph AC; Munch C
TI -
Ifosfamide encephalopathy presenting with asterixis.
SO - J Neurol Sci 2002 Jul 15;199(1-2):85-8
AD - Department of Neurology, Charite Hospital, Humboldt University,
Augustenburger Platz 1, 13353 Berlin, Germany. thomas.meyer@charite.de
CNS toxic effects of the antineoplastic agent ifosfamide (IFX) are
frequent and include a variety of neurological symptoms that can limit
drug use. We report a case of a 51-year-old man who developed severe,
disabling negative myoclonus of the upper and lower extremities after
the infusion of ifosfamide for plasmacytoma. He was awake, revealed no
changes of mental status and at rest there were no further motor
symptoms. Cranial magnetic resonance imaging and extensive laboratory
studies failed to reveal structural lesions of the brain and metabolic
abnormalities. An electroencephalogram showed continuous, generalized
irregular slowing with admixed periodic triphasic waves indicating
symptomatic encephalopathy. The administration of ifosfamide was
discontinued and within 12 h the asterixis resolved completely. In the
patient described, the presence of asterixis during infusion of
ifosfamide, normal laboratory findings and imaging studies and the
resolution of symptoms following the discontinuation of the drug suggest
that negative myoclonus is associated with the use of IFX.
25
UI - 12166074
AU - Moriyama T; Tozawa T; Matsuno K
TI -
[Tumor producing amylase]
SO - Rinsho Byori 2002 Jun;50(6):566-70
AD - Department of Laboratory Technology, College of Medical Technology,
Hokkaido University, Sapporo 060-0812.
The phenotype of tumor-producing amylase is usually salivary-type
amylase, in contrast, we experienced sialyl salivary-type amylase
detected in the sera of the patients with malignancies. Sialyl
salivary-type amylase, with an abnormal anodic migration, was detected
by isoamylase electrophoretic analysis in the sera of patients with
multiple myeloma and with ovarian cancer. The abnormal isoamylase bands
migrated toward the anode faster than the salivary isoamylase band(S2)
and were stained more strongly than S2 band. The isoamylases could be
separated from residual normal isoamylases in the sera of patients by
using gel permeation chromatography. The isoamylases were showed
sensitive by neuraminidase treatment and were reacted with anti-human
salivary monoclonal antibody.
26
UI - 11821971
AU - Finsterer J; Kladosek A; Gornik A; Birkner T
TI -
Transverse syndrome as the dominant feature of solitary cervical
plasmocytoma with dissemination.
SO - Spinal Cord 2002 Jan;40(1):44-7
AD - 2nd Neurological Department, Neurological Hospital Rosenhugel, Vienna,
Austria.
STUDY DESIGN: A case report of transverse syndrome secondary to
compression from an intravertebral plasmocytoma. OBJECTIVES: To report a
rare case of cervical cord compression. SETTING: Vienna, Austria. CASE
REPORT: A 47-year-old man presented with pain over the left scapula and
subsequent development of pain and sensory disturbance. Investigations
showed that the entire C7 vertebra was affected by a plasmocytoma.
Decompression was carried out but no stabilisation of the spinal column
was performed. Seven days after surgery the patient became paraplegic.
Chemotherapy produced no improvement. CONCLUSION: Transverse syndrome
may be a dominant feature of plasmocytoma and may resolve after
immediate decompression but may recur if the spinal column is not
stabilised.
27
UI - 12078798
AU - Deeb ME; Shargal Y; Merin G; Milgalter E
TI -
Incidental finding of myeloproliferative disorders during sternotomy.
SO - Ann Thorac Surg 2002 Jun;73(6):1951-2
AD - Department of Cardiothoracic Surgery, Hadassah Medical Center, Hebrew
University, Jerusalem, Israel.
We report 2 cases of myeloproliferative disorders discovered
incidentally at the time of routine coronary bypass surgery. Suspicion
of abnormal bone marrow tissue upon performing sternotomy and subsequent
sampling for frozen section made the diagnosis. The surgical plan was
changed, and partial revascularization without cardiopulmonary bypass
was performed.
28
UI - 1872566
AU - Hawkins RC
TI -
Pseudohyperphosphataemia in multiple myeloma.
SO - Ann Clin Biochem 1991 May;28 ( Pt 3)():226-8
AD - Department of Clinical Chemistry, Auckland Hospital, New Zealand.
Two cases of spurious hyperphosphataemia in patients with multiple
myeloma are presented. An unreduced phosphomolybdate method without
dialysis was used and the falsely raised values are shown to be due to
the formation of a proteinaceous suspension in the reaction mixture.
Such interference may be more prevalent than is generally recognized,
and care should be taken to identify the problem in patients with
myeloma.
29
UI - 1626934
AU - Lai LC; McClure D; Cornell C
TI -
Pseudohyperphosphataemia in multiple myeloma.
SO - Ann Clin Biochem 1992 Mar;29 ( Pt 2)():237
30
UI - 1308117
AU - Larner AJ
TI -
Pseudohyperphosphataemia in multiple myeloma.
SO - Ann Clin Biochem 1992 Sep;29 ( Pt 5)():571-2
31
UI - 11892717
AU - Bachleitner-Hofmann T; Machold K; Knobler R; Drach J; Grumbeck E;
TI -
Gisslinger H
Marked and sustained improvement of systemic sclerosis following
polychemotherapy for coexistent multiple myeloma.
SO - Clin Exp Rheumatol 2002 Jan-Feb;20(1):85-8
AD - Department of Internal Medicine I, University of Vienna, Austria.
We present the case of a patient who had systemic sclerosis (SSc) with
progressive cutaneous and pulmonary involvement and a coexisting
monoclonal gammopathy which gradually progressed to overt multiple
myeloma. Strikingly, successful VMCP (vincristine, melphalan,
cyclophosphamide and prednisolone) polychemotherapy for myeloma was
accompanied by a marked and sustained improvement of SSc that has
persisted for 2 years after chemotherapy. Most noticeable was a
substantial skin softening in our patient, with a > 50% reduction in the
skin thickness score following VMCP treatment. Our case suggests that
polychemotherapy may represent a promising treatment option in patients
with SSc who are refractory to available treatments.
32
UI - 11510469
AU - Fonesca R; Oken MM; Greipp PR; Eastern Cooperative Oncology Group
TI -
Myeloma Group
The t(4;14)(p16.3;q32) is strongly associated with chromosome 13
abnormalities in both multiple myeloma and monoclonal gammopathy of
undetermined significance.
SO - Blood 2001 Aug 15;98(4):1271-2
33
UI - 12101201
AU - Xu JL; Lai R; Kinoshita T; Nakashima N; Nagasaka T
TI -
Proliferation, apoptosis, and intratumoral vascularity in multiple
myeloma: correlation with the clinical stage and cytological grade.
SO - J Clin Pathol 2002 Jul;55(7):530-4
AD - Department of Laboratory Medicine, Nagoya University School of Medicine,
Tsurumai-cho 65, Showa-ku, Japan.
AIMS: Abnormalities involving proliferation, apoptosis, and angiogenesis
are important in tumorigenesis. The purpose of this study was to examine
these three biological processes, and their relation with the clinical
stage and cytological grade in multiple myeloma (MM). METHODS: Fifty
four newly diagnosed patients with MM were studied by
immunohistochemistry using bone marrow clot sections. Proliferation and
apoptosis were evaluated for the proportion of MM cells (indicated by
morphology and CD138 reactivity) positive for the Ki67 antigen and
single stranded DNA (ssDNA), respectively. Angiogenesis was evaluated by
measuring the intratumoral microvessel density (IMVD) and by assessing
the immunoreactivity of vascular endothelial growth factor (VEGF).
RESULTS: There were 30 men and 24 women (median age, 65 years; range,
37-84). At initial presentation, 15 (28%) were in Durie stage I, 15
(28%) in stage II, and 24 (44%) in stage III. Advanced clinical stage
correlated with high cytological grade (p < 0.03). The medians for Ki67,
ssDNA, and IMVD were 4.4% (range, 0-15%), 0.2% (range, 0-2.8%), and 15.5
(range, 0-63), respectively. Among these three continuous parameters,
the only significant correlation was that between Ki67 and IMVD (p <
0.0001). Both Ki67 and IMVD also correlated with the clinical stage,
cytological grade, and VEGF positivity (p <0.05). No correlation was
found between ssDNA and all of the other parameters. CONCLUSIONS: These
data suggest that proliferation is associated with angiogenesis in MM.
Furthermore, proliferation and angiogenesis, but not apoptosis, may be
important in disease progression. Lastly, increased production of VEGF
may be one of the contributing factors to the increase in intratumoral
vascularity seen in advanced MM.
34
UI - 12135668
AU - Gupta D; Podar K; Tai YT; Lin B; Hideshima T; Akiyama M; LeBlanc R;
TI -
Catley L; Mitsiades N; Mitsiades C; Chauhan D; Munshi NC; Anderson KC
beta-lapachone, a novel plant product, overcomes drug resistance in
human multiple myeloma cells.
SO - Exp Hematol 2002 Jul;30(7):711-20
AD - Jerome Lipper Myeloma Center, Department of Adult Oncology, Dana Farber
Cancer Institute, Boston, MA 02115, USA.
OBJECTIVE: To evaluate the anti-tumor potential of beta-lapachone in
multiple myeloma (MM) cell lines (U266, RPMI8226, and MM.1S); MM cell
lines resistant to dexamethasone (MM.1R), melphalan (RPMI8226/LR5),
doxorubicin (RPMI8226/DOX40), and mitoxantrone (RPMI8226/ MR20); and MM
cells from patients (MM1-MM4). MATERIALS AND METHODS: Cytotoxicity of
beta-lapachone was assessed by MTT and [3H]-thymidine uptake assays.
Apoptosis was analyzed using propidium iodide staining, DNA
fragmentation, TUNEL assay, caspase-9 colorimetric assay, and
immunoblotting for caspase-3, poly (ADP-ribose) polymerase (PARP), and
caspase-8 cleavage products. Paracrine growth of MM cells was assessed
by [3H]-thymidine uptake in cultures of bone marrow stromal cells
(BMSCs) and MM cells. Interleukin-6 (IL-6) and vascular endothelial
growth factor (VEGF) secretion in the culture supernatants was measured
by specific enzyme-linked immunosorbent assays (ELISAs). RESULTS:
beta-lapachone showed significant cytotoxicity in MM cells (IC(50): 4-8
microM). In contrast, normal peripheral blood mononuclear cells (PBMCs)
and BMSCs from MM patients were relatively resistant (IC(50): 8-16
microM). IL-6 did not protect against beta-lapachone-induced apoptosis
in MM.1S cells, and dexamethasone showed additive cytotoxicity.
beta-lapachone also decreased binding of MM.1S cells to BMSCs; abrogated
IL-6 and VEGF secretion triggered by adhesion of BMSCs to MM.1S cells;
reduced proliferation of MM.1S cells adherent to BMSCs; and decreased
intracellular adhesion molecule-1 (ICAM-1) expression on MM.1S cells.
Furthermore, beta-lapachone induced typical PARP cleavage, increased
caspase-9 proteolytic activity, and activation of caspase-3, without
activation of caspase-8 in U266 cells. CONCLUSION: These studies provide
a framework for clinical evaluation of beta-lapachone to improve the
outcome for patients with MM.
35
UI - 12173715
AU - Rajkumar SV; Gertz MA; Kyle RA; Greipp PR; Mayo Clinic Myeloma, Amyloid,
TI -
and Dysproteinemia Group
Current therapy for multiple myeloma.
SO - Mayo Clin Proc 2002 Aug;77(8):813-22
AD - Division of Hematology and Internal Medicine, Mayo Clinic, Rochester,
Minn 55905, USA. rajks@mayo.edu
Multiple myeloma is an incurable plasma cell malignancy that accounts
for 10% of all hematologic cancers. For decades the mainstay of therapy
has been the use of melphalan and prednisone; with this regimen, the
median survival is approximately 3 years. Recently, important advances
were made that have substantially altered the manner in which patients
with myeloma are treated. Newly diagnosed patients with good performance
status are now treated with autologous stem cell transplantation,
resulting in improved survival. Because of the increasing use of
transplantation as initial therapy, several therapeutic issues have
emerged: the role of tandem transplantation, early vs delayed
transplantation, and the role of allogeneic transplantation. The
pronounced activity of thalidomide in patients with refractory myeloma
represents another important advance. This has prompted the study of
several novel agents in the treatment of myeloma, at least 2 of which
appear promising. Supportive care measures also have improved, including
the use of bisphosphonates to prevent osteolytic lesions. The purpose of
this review is to summarize recent advances and provide an
evidence-based approach to the treatment of multiple myeloma.
36
UI - 12173332
AU - Mohrbacher AF; Gregory SA; Gabriel DA; Rusk JM; Giles FJ
TI -
Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with
multiple myeloma. A phase II International Oncology Study Group study.
SO - Cancer 2002 May 15;94(10):2645-52
AD - Department of Hematology, Norris Comprehensive Cancer Center, University
of Southern California, 1441 Eastlake Avenue, Los Angeles, CA 90033,
USA. mohrbach@hsc.usc.edu
BACKGROUND: Liposomal daunorubicin is an effective cytotoxic agent in
patients with Kaposi sarcoma and hematologic malignancies.
Anthracycline-based chemotherapy regimens, such as
vincristine/doxorubicin/dexamethasone (VAD), are standard in the
treatment of patients with multiple myeloma (MM). Cardiotoxicity remains
a limiting factor in dose escalation of anthracyclines, and multidrug
resistance (MDR) develops rapidly on exposure to anthracyclines.
Liposomal daunorubicin was designed in an attempt to overcome MDR and to
reduce anthracycline-related toxicities. Thus, an open-label, Phase II
clinical study was conducted by the International Oncology Study Group
to assess the efficacy and safety of intravenous liposomal daunorubicin
at a dose of 100 mg/m2 given every 3 weeks for a maximum of 6 cycles in
patients with recently diagnosed MM (n = 4 patients) or
recurrent/refractory MM (n = 37 patients). METHODS: Liposomal
daunorubicin was administered as a single agent for the initial two
cycles of therapy, and dexamethasone was added to all subsequent cycles.
The primary study end point was response rates. Thirty-eight patients
were treated, 35 of whom were evaluable for response. RESULTS: A partial
response was achieved in six patients (17%), including one patient with
disease that previously was refractory to VAD therapy. Stable disease
was observed in 22 patients (63%). The principal toxicity was
myelosuppression. Grade 3 or 4 hematologic toxicities included
granulocytopenia (26%), anemia (Grade 3 only; 11%), thrombocytopenia
(11%), and febrile neutropenia (13%). The median survival in 35 patients
with recurrent disease was 7.6 months. CONCLUSIONS: Liposomal
daunorubicin had activity in this population of poor-risk patients that
was comparable to the activity of standard regimens. Further studies of
this agent in combination with other anti-MM agents are warranted.
37
UI - 12091368
AU - Brander C; Raje N; O'Connor PG; Davies F; Davis J; Chauhan D; Hideshima
TI -
T; Martin J; Osmond D; Kedes DH; Walker BD; Scadden DT; Anderson KC
Absence of biologically important Kaposi sarcoma-associated herpesvirus
gene products and virus-specific cellular immune responses in multiple
myeloma.
SO - Blood 2002 Jul 15;100(2):698-700
AD - Partners AIDS Research Center, Massachusetts General Hospital,
Charlestown, MA, USA.
Kaposi sarcoma-associated herpesvirus (KSHV) has been associated with
several diseases, but the association between KSHV and multiple myeloma
(MM) remains controversial. To address this issue, we studied patients
with MM for the presence of viral RNA transcripts as well as
KSHV-specific cellular immune responses. Highly sensitive reverse
transcription-polymerase chain reaction assays for detection of viral
transcripts of KSHV open reading frame (ORF) 26, ORF72, and ORF74 did
not detect viral gene transcripts in long-term cultures of bone marrow
stromal cells from 23 patients with MM. Moreover, sensitive assays for
KSHV ORF65-specific and ORF73-specific cytotoxic T-lymphocyte (CTL)
activity that readily and routinely detect CTLs specific for ORF65 and
ORF73 in patients positive for human immunodeficiency virus and KSHV did
not show any specific responses in 16 patients with MM, despite the
presence of positive Epstein-Barr virus-specific CTLs in all cases.
These data therefore do not show a biologically important association
between ongoing KSHV infection and MM.
38
UI - 12187809
AU - Kikuchi M; Inagaki T; Ueda R
TI -
[A case of multiple myeloma with infiltration into skeletal muscle after
injections of a granulocyte-colony stimulating-factor]
SO - Nippon Ronen Igakkai Zasshi 2002 Jul;39(4):433-8
AD - Second Department of Internal Medicine, Nagoya City University Medical
School.
Multiple myelomas often occur in elderly people with complications due
to aging. A 54-year-old man was first admitted with cerebral infarction,
that was followed by partial remission after chemotherapy. The karyotype
of the bone marrow cells was 46, XY, and no p53 gene mutations were
detected by polymerase chain reaction and single-strand conformation
polymorphism analysis. Chemotherapy (melphalan 10 mg, vindesine 3 mg,
ranimustine 150 mg, prednisolone 60 mg for 4 days) was performed in
subcutaneous injection of 50 micrograms of nartograstim for six days to
treat neutropenia, soft tissues around the right eye were swelled
gradually without redness, accompanied by elevation of the serum
creatine-kinase concentration. The swelling disappeared, and the enzyme
level normalized after discontinuation of nartograstim. In July, on the
sixth day of daily subcutaneous injection of 75 micrograms of filgrastim
after the same chemotherapy, similar swelling of the soft tissues around
the left eye became evident, and again this proved reversible. In July
2000, 40 mg of dexamethasone was infused, and after 5-day
subcutaneous-injection of 75 micrograms of filgrastim daily, the right
subclavicular soft tissue became swollen. He died of myocardial
infarction, and autopsy revealed infiltration of myeloma cells into the
right subclavicular muscle and bone marrow packed with myeloma cells.
This case suggests that myeloma cells can proliferate and infiltrate
into soft tissues on exposure to granulocyte-colony stimulating factors.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
